Background: Gut microbiota-derived urolithins may influence multiple myeloma (MM) disease progression and treatment. We analyzed urolithins and their associated microbiota in a retrospective cohort of 45 patients with active MM or premalignant disease using mass spectrometry and 16S rRNA gene sequencing.
Results: Patients with detectable levels of urolithin in serum and stool and a higher abundance of urolithin-related microbiota had a better outcome. Analysis of the effects of urolithin A (UroA) treatment ex vivo, in vitro, and in vivo revealed that UroA is cytotoxic against MM cell lines and modulates the cell cycle and mitochondrial activity. Notably, UroA inhibits the proliferation of primary MM cells in vitro and in a xenograft mouse model, improving overall survival. Finally, combination therapy with UroA and bortezomib has a synergistic effect in vitro, even in the presence of bortezomib resistance, and modulates signaling pathways involved in MM development.
Conclusions: UroA might be a potential therapeutic agent to halt MM disease progression or to overcome resistance when used in combination. Video Abstract.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869585 | PMC |
| http://dx.doi.org/10.1186/s40168-025-02045-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chromosome 1q (1q+) is the most frequent arm-level copy number gain in patients with MM and is associated with higher risk of progression and death despite recent therapeutic advances. Thus, developing targeted therapy for MM patients with 1q+ stands to benefit a large portion of patients in need of more effective management.
View Article and Find Full Text PDFMemory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma.
J Immunol
January 2025
Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, United States.
Natural killer (NK) cells are a promising approach for cellular cancer immunotherapy and are being investigated to treat patients with multiple myeloma (MM). We found that MM patient blood NK cell frequencies were normal with increased activating receptors and cytotoxic granules, without evidence of functional exhaustion. Despite this activated state, MM target cells were resistant to conventional NK cells by unclear mechanisms.
View Article and Find Full Text PDFSpleen Involvement at Diagnosis of Multiple Myeloma: A Case Report and Literature Review.
Cancer Rep (Hoboken)
March 2025
UOC Haematology, ASL Viterbo-Santa Rosa Hospital, Viterbo, Italy.
Background: Multiple myeloma (MM) is more often characterized by clonal plasma cell proliferation restricted to the bone marrow. However, a small percentage of patients with MM develop extramedullary disease (EMD): this type of localization is found in 1.7%-4.
View Article and Find Full Text PDFPlasma Cell-Rich Lymphoid Neoplasm in an Endocervical Polyp of the Uterine Cervix in a Perimenopausal 52-Year-Old Woman.
HCA Healthc J Med
February 2025
St David's North Austin Medical Center, Austin, Texas.
Background: The adaptive immune system consists of T and B lymphocytes, with some B lymphocytes further differentiating into plasma cells that secrete antibodies and make up the humoral immune system. Extramedullary plasmacytoma, mucosa-associated lymphoid tissue (MALT) lymphoma, and plasmablastic lymphoma are all plasma cell-rich lymphoid neoplasms that rarely present in the female genital tract. To date, few case reports of these malignancies arising within the uterine cervix exist.
View Article and Find Full Text PDFPlasmaCell CAD: A computer-aided diagnosis software tool for plasma cell recognition and characterization in microscopic images.
Int J Med Inform
March 2025
Department of Bioelectrics and Biomedical Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan 81746, Iran; Medical Image & Signal Processing Research Center, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan 81746, Iran. Electronic address:
Background And Objective: In the traditional diagnostic process for multiple myeloma cancer, a pathologist screens prepared blood samples using a microscope to detect, classify, and count plasma cells. This manual approach is time-consuming, exhausting, and prone to human errors. Consequently, medical experts and researchers are highly interested in any tool that partially or entirely automates this process.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!